share_log

HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $3 Price Target

Benzinga ·  Mar 8, 2023 06:13

HC Wainwright & Co. analyst Andrew Fein reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains $3 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment